Skip to main content
PMC home page
BMJ Open Access logoLink to BMJ Open Access
. 2015 Feb 2;75(4):652–659. doi: 10.1136/annrheumdis-2014-206191

Genome-wide association study of clinically defined gout identifies multiple risk loci and its association with clinical subtypes

Hirotaka Matsuo 1, Ken Yamamoto 2, Hirofumi Nakaoka 3, Akiyoshi Nakayama 1,4, Masayuki Sakiyama 1,5, Toshinori Chiba 1, Atsushi Takahashi 6, Takahiro Nakamura 6,7, Hiroshi Nakashima 8, Yuzo Takada 9, Inaho Danjoh 10,11, Seiko Shimizu 1, Junko Abe 1, Yusuke Kawamura 1, Sho Terashige 1, Hiraku Ogata 1, Seishiro Tatsukawa 1, Guang Yin 12,13, Rieko Okada 12, Emi Morita 12, Mariko Naito 12, Atsumi Tokumasu 14, Hiroyuki Onoue 15, Keiichi Iwaya 16, Toshimitsu Ito 17, Tappei Takada 18, Katsuhisa Inoue 19, Yukio Kato 20, Yukio Nakamura 10, Yutaka Sakurai 8, Hiroshi Suzuki 18, Yoshikatsu Kanai 21, Tatsuo Hosoya 22,23, Nobuyuki Hamajima 24, Ituro Inoue 3, Michiaki Kubo 25, Kimiyoshi Ichida 22,26, Hiroshi Ooyama 14, Toru Shimizu 27, Nariyoshi Shinomiya 1
PMCID: PMC4819613  PMID: 25646370

Abstract

Objective

Gout, caused by hyperuricaemia, is a multifactorial disease. Although genome-wide association studies (GWASs) of gout have been reported, they included self-reported gout cases in which clinical information was insufficient. Therefore, the relationship between genetic variation and clinical subtypes of gout remains unclear. Here, we first performed a GWAS of clinically defined gout cases only.

Methods

A GWAS was conducted with 945 patients with clinically defined gout and 1213 controls in a Japanese male population, followed by replication study of 1048 clinically defined cases and 1334 controls.

Results

Five gout susceptibility loci were identified at the genome-wide significance level (p<5.0×10−8), which contained well-known urate transporter genes (ABCG2 and SLC2A9) and additional genes: rs1260326 (p=1.9×10−12; OR=1.36) of GCKR (a gene for glucose and lipid metabolism), rs2188380 (p=1.6×10−23; OR=1.75) of MYL2-CUX2 (genes associated with cholesterol and diabetes mellitus) and rs4073582 (p=6.4×10−9; OR=1.66) of CNIH-2 (a gene for regulation of glutamate signalling). The latter two are identified as novel gout loci. Furthermore, among the identified single-nucleotide polymorphisms (SNPs), we demonstrated that the SNPs of ABCG2 and SLC2A9 were differentially associated with types of gout and clinical parameters underlying specific subtypes (renal underexcretion type and renal overload type). The effect of the risk allele of each SNP on clinical parameters showed significant linear relationships with the ratio of the case–control ORs for two distinct types of gout (r=0.96 [p=4.8×10−4] for urate clearance and r=0.96 [p=5.0×10−4] for urinary urate excretion).

Conclusions

Our findings provide clues to better understand the pathogenesis of gout and will be useful for development of companion diagnostics.

Keywords: Gout, Arthritis, Gene Polymorphism

Introduction

Gout is a common disease caused by deposition of monosodium urate (MSU) crystal due to hyperuricaemia.1 Humans have long suffered from gout as reported by Hippocrates 2500 years ago.2 There have been many famous patients with gout such as Sir Isaac Newton3 in the more recent past, and the numbers are still growing. From the pathophysiological point of view, gout can be classified into the renal underexcretion (RUE) type, the renal overload (ROL) type and the combined type based on clinical parameters4 (see online supplementary figure S1).

So far the genome-wide association studies (GWASs) of serum uric acid (SUA) level5–16 have identified a number of genetic loci including SLC2A9 (also known as GLUT9) and ABCG2 (also known as BCRP), and subsequent genetic and functional studies have revealed the biological and pathophysiological significance of ABCG2.4 17 18 Previous GWASs of gout reported a significant association with single-nucleotide polymorphisms (SNPs) of ABCG2, SLC2A9 with European ancestries,14 15 and of ALDH16A1 with Icelanders,14 while another study with African-American and European ancestries reported no significantly associated SNPs of gout.13 All of these studies were, however, performed with cases including self-reported patients with gout, in which clinical information was insufficient. Therefore, the relation to genetic heterogeneity underlying gout subtypes is also unclear. To better understand its genetic basis, we first performed a GWAS of clinically defined gout cases only. We then investigated the relationship between genetic variation and clinical types of gout.

Methods

Subjects

In the present study, we avoided use of self-reported gout cases and collected only clinically defined gout cases. All gout cases were clinically diagnosed as primary gout according to the criteria established by the American College of Rheumatology.19 All patients were assigned from among the Japanese male outpatients at the gout clinics of Midorigaoka Hospital (Osaka, Japan), Kyoto Industrial Health Association (Kyoto, Japan) or Ryougoku East Gate Clinic (Tokyo, Japan). Patients with inherited metabolism disorders including Lesch–Nyhan syndrome were excluded. Finally, 1994 male gout cases were registered as valid case participants. As controls, 2547 individuals were assigned from among Japanese men with normal SUA level (≤7.0 mg/dL) and no gout history, who were obtained from BioBank Japan11 20 and Japan Multi-Institutional Collaborative Cohort Study (J-MICC Study).21

Genotyping and quality control

Genome-wide genotyping was performed with Illumina HumanOmniExpress v1.0 (Illumina) in 946 cases and 1213 controls. Detailed methods of genotyping and quality control are shown in the online supplementary methods and figure S2. Finally, 570 442 SNPs passed filters for 945 cases and 1213 controls.

In total, 123 SNPs passing the significance threshold at p<1.0×10−5 in the GWAS stage were used for subsequent analyses. Among these SNPs, we examined their linkage disequilibrium (LD) and selected 16 SNPs for replication study (see online supplementary methods). These 16 SNPs were then genotyped by an allelic discrimination assay (Custom TaqMan Assay and By-Design, Applied Biosystems) with a LightCycler 480 (Roche Diagnostics).18 After quality control, subsequent statistical analysis was performed with 1048 cases and 1334 controls.

Statistical analyses for GWAS

We conducted an association analysis using a 2×2 contingency table based on the allele frequency, and p value of association was assessed by χ2 test. The quantile–quantile plot and the genomic inflation factor were used to assess the presence of systematic bias in the test statistics due to potential population stratification (see online supplementary methods and figure S3).

We then combined results from the GWAS and replication stages by meta-analysis.22 The inverse-variance fixed-effects model meta-analysis was used for estimating summary OR. Cochran's Q test23 and I2 statistic24 25 were examined to assess heterogeneity in ORs between GWAS and replication study. If heterogeneity was present by the statistical test (phet<0.05) or measurement (I2>50%), we implemented DerSimonian and Laird random-effects model meta-analysis.26 All the meta-analyses were performed using the STATA V.11.0. Genome-wide significance threshold was set to be α=5.0×10−8 to claim evidence of a significant association. Detailed methods of imputation and per cent variance are shown in the online supplementary methods.

Subtype analyses

Gout contains two distinct types, ‘ROL’ type and ‘RUE’ type. The ROL type was defined when urinary urate excretion (UUE) was over 25.0 mg/h/1.73 m2 (600 mg/day/1.73 m2)4 27–29 and their urate clearance (urate clearance/creatinine clearance ratio, FEUA) was 5.5% or over. Also, the RUE type was determined when UUE was 25.0 mg/h/1.73 m2 or under and FEUA was under 5.5%.4 30 31 Detailed methods of subtype analyses are described in the online supplementary methods.

Results

Genome-wide association study

Clinical characteristics of participants in this study are shown in online supplementary tables S1–S3. GWAS with 945 clinically defined gout cases and 1213 controls identified SNPs in three loci showing evidence of associations at the genome-wide significance level (p<5.0×10−8): rs2728125 of ABCG2 (p=1.5×10−27; OR=2.05), rs3775948 of SLC2A9 (p=6.7×10−15; OR=1.64) and rs2188380 of MYL2-CUX2 (p=5.7×10−13; OR=1.78, figures 1 and 2, table 1 and online supplementary figure S4).

Figure 1.

Figure 1

Open in a new tab

Manhattan plot of a genome-wide association analysis of gout. X-axis shows chromosomal positions. Y-axis shows -log10 p values. The upper and lower dotted lines indicate the genome-wide significance threshold (p=5.0×10−8) and the cut-off level for selecting single-nucleotide polymorphisms for replication study (p=1.0×10−5), respectively.

Figure 2.

Figure 2

Open in a new tab

Regional association plots for six discovered loci of gout. Five regions exceeding the genome-wide significance level (A–E) and one region showing a suggestive association (F). The highest association signal in each panel is located on ABCG2 (A), SLC2A9 (B), MYL2-CUX2 (C), GCKR (D), CNIH-2 (E) and MAP3K11 (F). Region within 250 kb from single-nucleotide polymorphism (SNP) showing lowest p value is displayed. (Top panel) Plots of -log10 p values for the test of SNP association with gout in the genome-wide association study stage. SNP showing the lowest p value is depicted as a pink diamond. Other SNPs are colour-coded according to the extent of linkage disequilibrium (measured in r2) with SNP showing the lowest p value. (Middle panel) Recombination rates (centimorgans per Mb) estimated from HapMap Phase II data are plotted. (Bottom panel) RefSeq genes. Genomic coordinates are based on Genomic Reference Consortium GRCh37.

Table 1.

Five SNPs showing significant association at genome-wide significance level and one suggestive SNP

GWAS† Replication study‡
Freq. Freq. Meta-analysis§
SNP¶ Chromosome Position (bp)†† Gene A1/A2‡‡ Cases Controls OR (95% CI) p Value Cases Controls OR (95% CI) p Value OR (95% CI) p Value
rs2728125 4 89 001 893 ABCG2 C/T 0.40 0.25 2.05 (1.80 to 2.34) 1.5×10−27 0.40 0.24 2.03 (1.79 to 2.30) 8.3×10−29 2.04 (1.86 to 2.23) 7.2×10−54
rs3775948 4 9 995 182 SLC2A9 G/C 0.68 0.56 1.64 (1.45 to 1.86) 6.7×10−15 0.67 0.56 1.57 (1.40 to 1.77) 7.6×10−14 1.61 (1.47 to 1.75) 5.5×10−27
rs2188380 12 111 386 127 MYL2-CUX2 T/C 0.85 0.76 1.78 (1.52 to 2.08) 5.7×10−13 0.86 0.78 1.73 (1.48 to 2.02) 2.0×10−12 1.75 (1.57 to 1.96) 1.6×10−23
rs1260326 2 27 730 940 GCKR T/C 0.62 0.54 1.39 (1.23 to 1.57) 1.2×10−7 0.61 0.55 1.32 (1.18 to 1.49) 2.8×10−6 1.36 (1.25 to 1.48) 1.9×10−12
rs4073582 11 66 050 712 CNIH-2 G/A 0.95 0.91 1.78 (1.39 to 2.29) 5.3×10−6 0.94 0.91 1.55 (1.23 to 1.96) 1.6×10−4 1.66 (1.40 to 1.96) 6.4×10−9
rs10791821** 11 65 368 323 MAP3K11 G/A 0.94 0.90 1.75 (1.38 to 2.22) 2.8×10−6 0.94 0.92 1.41 (1.12 to 1.77) 3.4×10−3 1.57 (1.33 to 1.85) 1.0×10−7
Open in a new tab

†945 gout cases and 1213 controls.

‡1048 gout cases and 1334 controls.

§Meta-analyses of the combined GWAS and replication samples (1993 gout cases and 2547 controls).

¶dbSNP rs number. A suggestive SNP is marked with ‘**’.

††SNP positions are based on the National Center for Biotechnology Information human genome reference sequence Build 37.4.

‡‡A1 is a risk-associated allele and A2 is a non-risk-associated allele.

Freq., frequency of A1; GWAS, genome-wide association study; SNP, single-nucleotide polymorphism.

Replication study was conducted with 1048 cases and 1334 controls. As a result, the three SNPs surpassing the genome-wide significance threshold in the GWAS stage were successfully replicated; rs2728125 (p=8.3×10−29; OR=2.03), rs3775948 (p=7.6×10−14; OR=1.57) and rs2188380 (p=2.0×10−12; OR=1.73). Additionally, two SNPs showed significant associations at p<3.1×10−3 (=0.05/16) with Bonferroni correction; rs1260326 of GCKR (p=2.8×10−6; OR=1.32) and rs4073582 of CNIH-2 (p=1.6×10−4; OR=1.55) as shown in table 1 and online supplementary table S4.

All five SNPs that showed significant associations in the replication study achieved genome-wide significance in the meta-analysis of GWAS and replication study (table 1): rs2728125 (pmeta=7.2×10−54; OR=2.04), rs3775948 (pmeta=5.5×10−27; OR=1.61), rs2188380 (pmeta=1.6×10−23; OR=1.75), rs1260326 (pmeta=1.9×10−12; OR=1.36) and rs4073582 (pmeta=6.4×10−9; OR=1.66). In addition, an intronic SNP of MAP3K11 (rs10791821) showed a suggestive level of association (pmeta=1.0×10−7; OR=1.57). There was >80% power to detect a risk variant for OR=1.6 at the genome-wide significance level (p<5.0×10−8) for an SNP with a minor allele frequency of 0.35 (see online supplementary table S5). Imputation was also performed with the GWAS genotyping data for 1 Mb across the identified SNPs of novel loci (rs2188380 of MYL2-CUX2, rs1260326 of GCKR, rs4073582 of CNIH-2 and rs10791821 of MAP3K11). SNPs that passed the significant threshold of GWAS stage (p<1.0×10−5) in this imputation are shown in online supplementary table S6A–D.

Two dysfunctional SNPs of ABCG2

We previously demonstrated that two dysfunctional SNPs of ABCG2, rs72552713 (Gln126Ter) and rs2231142 (Gln141Lys), were located on different haplotypes4 18 and strongly associated with hyperuricaemia and gout.4 18 32 Therefore, we additionally performed genotyping of these two SNPs by an allelic discrimination assay because SNPs are not on Illumina HumanOmniExpress V.1.0 (Illumina). SNP showing the highest significance in the present GWAS (rs2728125) was in strong LD with rs2231142 (r2=0.76) but not in LD with rs72552713 (r2=0.03). A multivariate logistic regression analysis including these three SNPs of ABCG2 showed that rs2728125 no longer had a significant association (p=0.19), but rs72552713 and rs2231142, that is, two non-synonymous SNPs, remained highly significant (see online supplementary table S7A, B), indicating that rs2728125 was merely a surrogate marker for rs2231142. Therefore, we used these two non-synonymous variants for subsequent analyses.

Cumulative effect of risk alleles for gout

Accumulation of the number of risk alleles of the gout-associated SNPs (rs3775948, rs2188380, rs1260326, rs4073582, rs72552713 and rs2231142) increased the probability of gout logarithmically. When setting the reference category as having four or fewer risk alleles, ORs for having 5, 6, 7, 8 and 9 or more risk alleles were 1.79 (p=3.5×10−3), 3.16 (p=2.3×10−10), 5.10 (p=9.7×10−21), 10.1 (p=5.3×10−39) and 18.6 (p=3.6×10−45), respectively (see online supplementary figure S5 and table S8).

Subtype analysis of gout

We examined type-specific ORs and the case–subtype heterogeneity test.33 The subgroup analysis (table 2) showed that the associations of two non-synonymous SNPs of ABCG2 (rs72552713 and rs2231142) were stronger for the ROL type (ORs=4.35 and 3.37, respectively) than for the RUE type (ORs=1.28 and 1.88, respectively). The differences in ORs between the gout types were highly significant (p=2.4×10−5 and 1.0×10−7, respectively). The association of rs3775948 of SLC2A9 was stronger for the RUE type (OR=1.94) than for the ROL type (OR=1.38). The case–subtype heterogeneity test showed a significant difference in ORs (p=2.7×10−4). The other SNPs evidenced no significant differences. Then, associations between SNPs and clinical parameters (FEUA and UUE) were assessed. Only SNPs that showed a significant difference in ORs between different gout types were significantly associated with FEUA and UUE (table 2 and online supplementary figure S6, table S9); the gout risk alleles of ABCG2 and SLC2A9 were associated with increased and decreased levels of these parameters, respectively. The effect of the risk allele of each SNP on clinical parameters showed significant linear relationships with OR in the case–subtype heterogeneity test, which was an estimate of the ratio of the case–control ORs for the gout types (r=0.96 [p=4.8×10−4] for FEUA and r=0.96 [p=5.0×10−4] for UUE) (figure 3).

Table 2.

Associations of seven SNPs with gout types

Freq. ROL type vs controls* RUE type vs controls* Case–subtype heterogeneity test
SNP† Gene ROL type RUE type OR (95% CI) p Value OR (95% CI) p Value OR (95% CI) p Value‡
rs3775948 SLC2A9 0.62 0.70 1.38 (1.14 to 1.68) 1.0×10−3 1.94 (1.63 to 2.31) 1.0×10−13 0.66 (0.53 to 0.83) 2.7×10−4
rs2188380 MYL2-CUX2 0.84 0.85 1.45 (1.11 to 1.89) 6.5×10−3 1.47 (1.16 to 1.86) 1.2×10−3 0.92 (0.68 to 1.25) 0.60
rs1260326§ GCKR 0.60 0.62 1.25 (1.04 to 1.50) 0.016 1.35 (1.15 to 1.58) 3.0×10−4 0.94 (0.77 to 1.14) 0.51
rs4073582 CNIH-2 0.95 0.94 1.96 (1.30 to 2.95) 1.2×10−3 1.51 (1.09 to 2.08) 0.013 1.26 (0.80 to 1.99) 0.32
rs10791821 MAP3K11 0.93 0.95 1.37 (0.96 to 1.96) 0.084 1.79 (1.26 to 2.54) 1.2×10−3 0.79 (0.51 to 1.23) 0.30
rs72552713§ ABCG2 0.067 0.029 4.35 (2.82 to 6.72) 3.0×10−11 1.28 (0.78 to 2.12) 0.32 2.90 (1.77 to 4.75) 2.4×10−5
rs2231142§ ABCG2 0.50 0.38 3.37 (2.76 to 4.12) 2.8×10−32 1.88 (1.58 to 2.24) 2.5×10−12 1.76 (1.43 to 2.17) 1.0×10−7
Open in a new tab

*We performed multivariate logistic regression analyses, in which all seven SNPs, alcohol drinking and body mass index were included in the model. In total, 1613 patients with gout and 1334 controls with genotypes for rs72552713 and rs2231142 of ABCG2, which were not on the Illumina OmniExpress platform, were used. Also, 375 and 509 patients with gout were grouped into ROL type and RUE type, respectively.

†dbSNP rs number.

‡p Values <0.05 are shown in bold.

§Non-synonymous SNPs (rs1260326, Leu446Pro; rs72552713, Gln126Ter; and rs2231142, Gln141Lys).

Freq., frequency of risk-associated allele; ROL, renal overload; RUE, renal underexcretion; SNP, single-nucleotide polymorphism.

Figure 3.

Figure 3

Open in a new tab

Relationships between effects of risk alleles on clinical parameters and ORs in case–subtype heterogeneity test. (A) FEUA and (B) urinary urate excretion (UUE). The seven single-nucleotide polymorphisms (SNPs) listed in table 2 were examined. OR in case–subtype heterogeneity test is an estimate of the ratio of the case–control OR for the renal overload (ROL) type to that for the renal underexcretion (RUE) type. If an SNP has a stronger effect for the ROL type than for the RUE type, it takes a value >1. Diamonds and lines represent point estimates and their 95% CIs. Pearson's correlation coefficient (r) between the effect on clinical parameters and natural logarithm of OR in case–subtype heterogeneity test and its significance were examined. FEUA, fractional excretion of urate clearance.

Discussion

Through the GWAS with clinically defined cases, we identified five gout-associated loci that showed different association patterns in subtype analysis. Previous GWASs of SUA5–16 showed genome-wide significant associations with ABCG2, SLC2A9 and GCKR. These genes were also reported to have significant associations with gout as a consequence of hyperuricaemia.13–15 The present study revealed for the first time that three loci (GCKR, MYL2-CUX2 and CNIH-2) were associated with gout at the genome-wide significance level. In particular, MYL2-CUX2 and CNIH-2 are novel loci for gout.

The total variance explained by the seven SNPs was estimated to be 9.0% (see online supplementary methods): three SNPs of well-known urate transporter genes (SLC2A9 and ABCG2) with large effects accounted for 6.9%, and the four SNPs identified in this GWAS with modest effects explained 2.1%. Additional discoveries of unidentified genetic variants by performing a meta-analysis of GWAS data sets will improve the explained genetic variation of gout.

ABCG2 and SLC2A9 are well-known urate transporter genes for urate excretion17 18 and renal urate reabsorption,34 35 respectively. ABCG2 is identified to have an association with SUA levels by recent GWASs.9–16 Subsequent genetic and functional analysis17 18 revealed that ABCG2 is a high-capacity urate exporter and shows the reduced transport of urate by a common half-functional variant, rs2231142 (Gln141Lys). We also demonstrated that common dysfunctional genotype combinations of ABCG2 gene (non-functional rs72552713 [Gln126Ter] and rs2231142) are a major cause of hyperuricaemia and gout,18 especially for early-onset gout.32 We earlier found that the risk alleles of these two SNPs reside on different haplotypes,4 18 indicating independent risks of gout. Recently, these dysfunctional SNPs were revealed to decrease extrarenal (intestinal) urate excretion and to cause ROL hyperuricaemia,4 through studies with hyperuricaemic patients4 and Abcg2-knockout mice.4 36 This is consistent with the fact that ABCG2 exporter is expressed on the apical membrane in several tissues, including intestine37 and kidney,38 which have urate-excreting functions in humans.

SLC2A9 is a member of the glucose transporter (GLUT) family. SLC2A9 was found to transport urate,7 34 and several GWAS have demonstrated an association of SLC2A9 with SUA levels.5–16 SLC2A9 has two isoforms, GLUT9L (long isoform) and GLUT9S (short isoform),34 and is highly expressed in the kidney proximal tubules in humans.39 Genetic and functional analysis34 35 with patients with renal hypouricaemia (RHUC) revealed that RHUC is caused by dysfunctional mutations in SLC2A9, which decrease urate reabsorption in the renal proximal tubules. For example, non-functional mutations of either GLUT9L (Arg198Cys and Arg380Trp) or GLUT9S (Arg169Cys and Arg351Trp, corresponding to Arg198Cys and Arg380Trp in GLUT9L), which were found from patients with RHUC, dramatically reduced the urate transport activity.34 Therefore, SLC2A9 plays an important role in renal urate reabsorption.34 Thus, SLC2A9 is a causative gene for RHUC type 2,34 40 which was confirmed by the report of homozygous mutations in patients with RHUC type 2.35 In our subtype analysis, OR of RUE type was higher than that of ROL type (OR=1.94 and 1.38, respectively, table 2), which is compatible with the fact that SLC2A9 is a transporter for urate reabsorption in human kidney.

Glucokinase regulatory protein (GCKR) controls the activity of glucokinase, which is a major glucose sensor for insulin secretion. GCKR regulates the first step of glycolysis, the phosphorylation of glucose to glucose-6-phosphate.41 42 Glucokinase activity is controlled by GCKR, which binds to glucokinase and suppresses its function in the postabsorptive phase. On the other hand, this binding is loosened in the postprandial phase, so that glucokinase could adopt the glycolysis.43 So far, the gout risk allele of rs1260326 (Leu446Pro) has been reported to be associated with lower fasting glucose levels, and inversely, higher levels of triglyceride43–45 and SUA.10 12 15 An association of GCKR with dyslipidaemia has also been reported.46

MYL2 encodes a regulatory light chain associated with cardiac myosin β (or slow) heavy chain. MYL2 mutations are associated with mid-left ventricular-type hypertrophic cardiomyopathy. In addition, its association with high-density lipoprotein cholesterol metabolism was previously reported.47 CUX2 regulates cell-cycle progression48 and plays important roles in neural progenitor development in the central nervous system.48 49 Its association with type 1 diabetes has also been reported.50 Thus, rs2188380 of MYL2-CUX2 showed an association with gout because MYL2 and CUX2 might influence such metabolic pathways. Rs2188380 locates near rs653178 of ATXN2 (see online supplementary figure S7), which was reported by Köttgen et al15 to have an association with SUA. Rs653178 is, however, monomorphic in the Japanese population of the HapMap project,51 and we also confirmed it in our samples by genotyping >250 replication cases. Conversely, rs2188380 of MYL2-CUX2 is monomorphic in European and African populations,51 while rs2188380 is a common variant in the Japanese population (table 1). Therefore, this SNP was identified as a novel locus of gout in the present study. The differences in study populations could be one of the reasons why rs2188380 was not found in a large European-driven GWAS on urate and gout.15 Further analyses including fine mapping and functional analysis are required in this region.

CNIH-2 regulates the function of glutamate receptors of the AMPA-subtype assembly at the cell surface of various neurons and glial cells.52 53 CNIH-2 modulates AMPA receptor gating by increasing its cell surface expression. The newly identified rs4073582 of CNIH-2 was in strong LD with rs801733 in PACS1 (r2=0.97, figure 2E and see online supplementary figure S4E), which is reported to be associated with severe obesity.54 Accordingly, PACS1 can also be a good candidate for a gout susceptibility gene. Additional genetic dissection and functional analysis will be needed to determine whether these genes or others could play roles with true causality at this locus. Since Okada et al16 previously reported the association between SUA and rs504915 of NRXN2, which is near CNIH-2 and MAP3K11, we examined their relationships. They are not in strong LD (see online supplementary table S10), and the association of rs4073582 and rs10791821 remained significant after adjustment with rs504915 (see online supplementary table S11). Therefore, rs4073582 of CNIH-2, rs10791821 of MAP3K11 and rs504915 of NRXN2 are revealed to be independent of each other.

MAP3K11, also known as mixed lineage kinase 3 (MLK3), is a MAP kinase member and plays a significant role in the activation of c-Jun N-terminal kinase (JNK), a stress-activated protein kinase.55 Signalling from the small GTP-binding proteins Rac1 and Cdc42 induces MLK3 to activate the MEKK-SEK-JNK kinase cascade. Interestingly, the JNK pathway is activated when monocytes/macrophages phagocytose MSU crystals,56 which cause gouty arthritis. The SNP rs10791821 of MAP3K11 has been associated with the expression level of MAP3K11 in monocytes,57 and therefore, is likely to be a regulatory SNP. However, further study is required to confirm precise involvement of MAP3K11 in the development of gout.

Other genes (CCDC63, C2orf16, ZNF512, RAB1B, EHBP1L1 and KCNK7) near each of the novel loci, which are found by imputation analysis (see online supplementary table S6A–D), could also be candidate genes of gout, and further studies including functional analyses are warranted.

Most of the gout-related genes are also associated with SUA.15 In the present study design, to identify novel gout risk loci, clinically defined gout and normouricaemic controls were recruited. Therefore, further investigations with different study designs will be needed to identify gout loci associated with crystal deposition and inflammation.

We further investigated the cumulative effect of risk alleles of the five significant loci (ABCG2, SLC2A9, MYL2-CUX2, GCKR and CNIH-2) on gout risk. The result showed that individuals with five or more risk alleles had a higher risk for gout compared with those having four or fewer risk alleles. The more risk alleles in an individual, the higher became the risk of gout.

Furthermore, the relationship between genetic variation and clinical types of gout was investigated. The results of subtype analyses (table 2, figure 3 and online supplementary figure S6, table S9) indicate that the alleles closely associated with the risk of specific gout type represented differential effects on clinical parameters (FEUA and UUE). This allows the estimation of disturbed urate excretion pathways. An increase of FEUA and UUE by the risk alleles of ABCG2 leads to the overloading effect on renal urate excretion and causes the ROL-type gout (figure 4A). These estimations are consistent with our previous finding obtained from Abcg2-knockout mouse models and hyperuricaemic patients.4 In contrast, the reduction of FEUA and UUE by the risk allele of SLC2A9 reflects a decreased renal urate excretion, thereby increasing the risk of the RUE-type gout (figure 4B). The present study demonstrated that the combination of GWAS of patients with clinically defined gout with actual clinical data is an effective method to analyse genetic heterogeneity among different types of gout.

Figure 4.

Figure 4

Open in a new tab

Differential effects by risk allele on clinical parameters and gout. (A) The risk alleles of ABCG2 increase UUE and FEUA, which leads to the overloading effect on renal urate excretion and increases the risk of the ROL-type gout. Therefore, patients with risk alleles for the ROL-type gout would be given urate synthesis inhibitors. (B) The risk allele of SLC2A9 reduces UUE and FEUA, which reflects a decreased renal urate excretion, thereby increasing the risk of the RUE-type gout. Patients with risk alleles for the RUE-type gout would be administered uricosuric agents. FEUA, fractional excretion of urate clearance; ROL, renal overload; RUE, renal underexcretion; SUA, serum uric acid; UUE, urinary urate excretion.

In summary, we conducted the first GWAS using patients with clinically defined gout only and identified five loci containing two novel loci. Moreover, identified SNPs showed differential effects on different gout types and affected clinical parameters underlying specific types. Thus, genetic testing for gout may well be introduced into future companion diagnostics. For example, patients with risk alleles for ROL-type gout would be given urate synthesis inhibitors31 58 such as allopurinol and febuxostat, while patients with risk alleles for RUE-type gout would be administered uricosuric agents31 58 including benzbromarone and lesinurad, a selective uric acid reabsorption inhibitor that has just finished its phase III study.59 60 Exploring genetic heterogeneity among different gout types will deepen understanding of the aetiology of gout and serve to categorise patients for future personalised treatment.

Supplementary Material

Web supplement

Acknowledgments

We would like to thank all the participants involved in this study. We also thank members of the BioBank Japan Project and Japan Multi-Institutional Collaborative Cohort Study (J-MICC Study) Shizuoka Field for supporting the study. We are indebted to K. Gotanda, Y. Morimoto, N. Katsuta, Y. Utsumi, Y. Kato, H. Sasaki, Y. Takashima, J. Sato, H. Inoue, C. Okada, S. Takeuchi, N. Otani, S. Tomura (National Defense Medical College), T. Tamatsukuri (Jikei University School of Medicine), Y. Oikawa and K. Niwa (Toho University) for genetic analysis; S. Ushida (Ikagaku), H. Fujiwara (Midorigaoka Hospital), A. Hishida and K. Wakai (Nagoya University) for sample collection; M. Hosoyamada, S. Fujimori (Teikyo University), T. Shimizu, T. Sugiura (Kanazawa University), H. Sato (National Defense Medical College), K. Shimono (Toho University) and T. Makino (Nagoya City University) for helpful discussion.

Footnotes

Contributors: HM, KY, HNakaoka, AN, MS, TC, II and NS conceived and designed the experiments. ATakahashi, TN, HNakashima, YT, TT, YS, HS, YKanai, TH and MK assisted with research design. HM, AN, MS, TC, ATokumasu, KIchida, HOoyama and TS collected and analysed clinical data of cases. ATakahashi, GY, RO, EM, MN, NH and MK collected and analysed clinical data of controls. HM, KY, AN, MS, TC, YT, ID, SS, JA, YKawamura, STerashige, HOgata, STatsukawa, YN and NS performed genetic analysis. HNakaoka, ATakahashi, TN, HNakashima and YS performed statistical analysis. HM, KY, HNakaoka, AN, MS, TC, ATakahashi, TN, HNakashima, MK, and NS analysed the data. TN, HNakashima, HOnoue, KIwaya, TI, TT, KInoue, YKato and II provided intellectual input and assisted with the preparation of the manuscript. HM, KY, HNakaoka, AN, MS, TC, ATakahashi and NS wrote the paper.

Funding: This work was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan including the MEXT KAKENHI (Grant numbers 221S0002, 25293145, 22689021, 25670307), the Ministry of Health, Labour and Welfare of Japan, the Ministry of Defense of Japan, the Japan Society for the Promotion of Science, the Kawano Masanori Memorial Foundation for Promotion of Pediatrics and the Gout Research Foundation of Japan. The BioBank Japan Project and J-MICC Study (221S0001) were supported by MEXT of Japan.

Competing interests: HM, TT and NS have a patent pending based on the work reported in this paper. Other authors have declared that no competing interests exist.

Patient consent: Obtained.

Ethics approval: All procedures involved in this study were approved by the institutional ethical committees of National Defense Medical College, Nagoya University and RIKEN, and all procedures involved were performed in accordance with the Declaration of Helsinki.

Provenance and peer review: Not commissioned; externally peer reviewed.

References

  • 1.Kippen I, Klinenberg JR, Weinberger A, et al. . Factors affecting urate solubility in vitro. Ann Rheum Dis 1974;33:313–17. 10.1136/ard.33.4.313 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Nuki G, Simkin PA. A concise history of gout and hyperuricemia and their treatment. Arthritis Res Ther 2006;8(Suppl 1):S1 10.1186/ar1906 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Johnson RJ, Rideout BA. Uric acid and diet--insights into the epidemic of cardiovascular disease. N Engl J Med 2004;350:1071–3. 10.1056/NEJMp048015 [DOI] [PubMed] [Google Scholar]
  • 4.Ichida K, Matsuo H, Takada T, et al. . Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun 2012;3:764 10.1038/ncomms1756 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Li S, Sanna S, Maschio A, et al. . The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts. PLoS Genet 2007;3:e194 10.1371/journal.pgen.0030194 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Döring A, Gieger C, Mehta D, et al. . SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nat Genet 2008;40:430–6. 10.1038/ng.107 [DOI] [PubMed] [Google Scholar]
  • 7.Vitart V, Rudan I, Hayward C, et al. . SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 2008;40:437–42. 10.1038/ng.106 [DOI] [PubMed] [Google Scholar]
  • 8.McArdle PF, Parsa A, Chang YP, et al. . Association of a common nonsynonymous variant in GLUT9 with serum uric acid levels in old order Amish. Arthritis Rheum 2008;58:2874–81. 10.1002/art.23752 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Dehghan A, Köttgen A, Yang Q, et al. . Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet 2008;372:1953–61. 10.1016/S0140-6736(08)61343-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Kolz M, Johnson T, Sanna S, et al. . Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet 2009;5:e1000504 10.1371/journal.pgen.1000504 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Kamatani Y, Matsuda K, Okada Y, et al. . Genome-wide association study of hematological and biochemical traits in a Japanese population. Nat Genet 2010;42:210–15. 10.1038/ng.531 [DOI] [PubMed] [Google Scholar]
  • 12.Yang Q, Köttgen A, Dehghan A, et al. . Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circ Cardiovasc Genet 2010;3:523–30. 10.1161/CIRCGENETICS.109.934455 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Tin A, Woodward OM, Kao WH, et al. . Genome-wide association study for serum urate concentrations and gout among African Americans identifies genomic risk loci and a novel URAT1 loss-of-function allele. Hum Mol Genet 2011;20:4056–68. 10.1093/hmg/ddr307 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Sulem P, Gudbjartsson DF, Walters GB, et al. . Identification of low-frequency variants associated with gout and serum uric acid levels. Nat Genet 2011;43:1127–30. 10.1038/ng.972 [DOI] [PubMed] [Google Scholar]
  • 15.Köttgen A, Albrecht E, Teumer A, et al. . Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet 2013;45:145–54. 10.1038/ng.2500 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Okada Y, Sim X, Go MJ, et al. . Meta-analysis identifies multiple loci associated with kidney function-related traits in east Asian populations. Nat Genet 2012;44:904–9. 10.1038/ng.2352 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Woodward OM, Köttgen A, Coresh J, et al. . Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc Natl Acad Sci U S A 2009;106:10338–42. 10.1073/pnas.0901249106 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Matsuo H, Takada T, Ichida K, et al. . Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population. Sci Transl Med 2009;1:5ra11. [DOI] [PubMed] [Google Scholar]
  • 19.Wallace SL, Robinson H, Masi AT, et al. . Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20:895–900. 10.1002/art.1780200320 [DOI] [PubMed] [Google Scholar]
  • 20.Nakamura T, Shi D, Tzetis M, et al. . Meta-analysis of association between the ASPN D-repeat and osteoarthritis. Hum Mol Genet 2007;16:1676–81. 10.1093/hmg/ddm115 [DOI] [PubMed] [Google Scholar]
  • 21.Hamajima N, J-MICC Study Group. The Japan Multi-Institutional Collaborative Cohort Study (J-MICC Study) to detect gene-environment interactions for cancer. Asian Pac J Cancer Prev 2007;8:317–23. [PubMed] [Google Scholar]
  • 22.Nakaoka H, Inoue I. Meta-analysis of genetic association studies: methodologies, between-study heterogeneity and winner's curse. J Hum Genet 2009;54:615–23. 10.1038/jhg.2009.95 [DOI] [PubMed] [Google Scholar]
  • 23.Cochran WG. The combination of estimates from different experiments. Biometrics 1954;10:101–29. 10.2307/3001666 [DOI] [Google Scholar]
  • 24.Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539–58. 10.1002/sim.1186 [DOI] [PubMed] [Google Scholar]
  • 25.Higgins JP, Thompson SG, Deeks JJ, et al. . Measuring inconsistency in meta-analyses. BMJ 2003;327:557–60. 10.1136/bmj.327.7414.557 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–88. 10.1016/0197-2456(86)90046-2 [DOI] [PubMed] [Google Scholar]
  • 27.Becker MA. Hyperuricemia and gout. In: Scriver CR, Childs B, Kinzler KW, Vogelstein B, eds. The Metabolic & Molecular Bases of Inherited Disease. 8th edn New York: McGraw-Hill, 2001:2513–35. [Google Scholar]
  • 28.Wortmann RL. Disorders of purine and pyrimidine metabolism. In: Fauci AS, Braunwald E, Kasper D, Hauser SL, Long DL, Jameson JL, et al. , eds Harrison's principles of internal medicine. 17th edn New York: McGraw-Hill, 2008:2444–9. [Google Scholar]
  • 29.Wortmann RL. Gout and hyperuricemia. Curr Opin Rheumatol 2002;14:281–6. 10.1097/00002281-200205000-00015 [DOI] [PubMed] [Google Scholar]
  • 30.Urano W, Taniguchi A, Anzai N, et al. . Sodium-dependent phosphate cotransporter type 1 sequence polymorphisms in male patients with gout. Ann Rheum Dis 2010;69:1232–4. 10.1136/ard.2008.106856 [DOI] [PubMed] [Google Scholar]
  • 31.The guideline revising committee of the Japanese Society of Gout and Nucleic Acid Metabolism. Diagnosis of hyperuricemia and gout. In: The guideline revising committee of the Japanese Society of Gout and Nucleic Acid Metabolism, ed. Guideline for the Management of Hyperuricemia and Gout. 2nd edn. Osaka: Medical Review, 2010:60–72. [Google Scholar]
  • 32.Matsuo H, Ichida K, Takada T, et al. . Common dysfunctional variants in ABCG2 are a major cause of early-onset gout. Sci Rep 2013;3:2014 10.1038/srep02014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Nakaoka H, Takahashi T, Akiyama K, et al. . Differential effects of chromosome 9p21 variation on subphenotypes of intracranial aneurysm: site distribution. Stroke 2010;41:1593–8. 10.1161/STROKEAHA.110.586529 [DOI] [PubMed] [Google Scholar]
  • 34.Matsuo H, Chiba T, Nagamori S, et al. . Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia. Am J Hum Genet 2008;83:744–51. 10.1016/j.ajhg.2008.11.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Dinour D, Gray NK, Campbell S, et al. . Homozygous SLC2A9 mutations cause severe renal hypouricemia. J Am Soc Nephrol 2010;21:64–72. 10.1681/ASN.2009040406 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Hosomi A, Nakanishi T, Fujita T, et al. . Extra-renal elimination of uric acid via intestinal efflux transporter BCRP/ABCG2. PLoS ONE 2012;7:e30456 10.1371/journal.pone.0030456 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Maliepaard M, Scheffer GL, Faneyte IF, et al. . Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001;61:3458–64. [PubMed] [Google Scholar]
  • 38.Huls M, Brown CD, Windass AS. , et al. The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. Kidney Int 2008;73:220–5. 10.1038/sj.ki.5002645 [DOI] [PubMed] [Google Scholar]
  • 39.Augustin R, Carayannopoulos MO, Dowd LO, et al. . Identification and characterization of human glucose transporter-like protein-9 (GLUT9): alternative splicing alters trafficking. J Biol Chem 2004;279:16229–36. 10.1074/jbc.M312226200 [DOI] [PubMed] [Google Scholar]
  • 40.Kawamura Y, Matsuo H, Chiba T, et al. . Pathogenic GLUT9 mutations causing renal hypouricemia type 2 (RHUC2). Nucleosides Nucleotides Nucleic Acids 2011;30:1105–11. 10.1080/15257770.2011.623685 [DOI] [PubMed] [Google Scholar]
  • 41.Brown KS, Kalinowski SS, Megill JR, et al. . Glucokinase regulatory protein may interact with glucokinase in the hepatocyte nucleus. Diabetes 1997;46:179–86. 10.2337/diab.46.2.179 [DOI] [PubMed] [Google Scholar]
  • 42.Slosberg ED, Desai UJ, Fanelli B, et al. . Treatment of type 2 diabetes by adenoviral-mediated overexpression of the glucokinase regulatory protein. Diabetes 2001;50:1813–20. 10.2337/diabetes.50.8.1813 [DOI] [PubMed] [Google Scholar]
  • 43.Hishida A, Morita E, Naito M, et al. . Associations of apolipoprotein A5 (APOA5), glucokinase (GCK) and glucokinase regulatory protein (GCKR) polymorphisms and lifestyle factors with the risk of dyslipidemia and dysglycemia in Japanese—a cross-sectional data from the J-MICC Study. Endocr J 2012;59:589–99. 10.1507/endocrj.EJ11-0310 [DOI] [PubMed] [Google Scholar]
  • 44.Vaxillaire M, Cavalcanti-Proenca C, Dechaume A, et al. . The common P446L polymorphism in GCKR inversely modulates fasting glucose and triglyceride levels and reduces type 2 diabetes risk in the DESIR prospective general French population. Diabetes 2008;57:2253–7. 10.2337/db07-1807 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Shen H, Pollin TI, Damcott CM, et al. . Glucokinase regulatory protein gene polymorphism affects postprandial lipemic response in a dietary intervention study. Hum Genet 2009;126:567–74. 10.1007/s00439-009-0700-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Dupuis J, Langenberg C, Prokopenko I, et al. . New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 2010;42:105–16. 10.1038/ng.520 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Kim YJ, Go MJ, Hu C, et al. . Large-scale genome-wide association studies in East Asians identify new genetic loci influencing metabolic traits. Nat Genet 2011;43:990–5. 10.1038/ng.939 [DOI] [PubMed] [Google Scholar]
  • 48.Iulianella A, Sharma M, Durnin M, et al. . Cux2 (Cutl2) integrates neural progenitor development with cell-cycle progression during spinal cord neurogenesis. Development 2008;135:729–41. 10.1242/dev.013276 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Franco SJ, Gil-Sanz C, Martinez-Garay I, et al. . Fate-restricted neural progenitors in the mammalian cerebral cortex. Science 2012;337:746–9. 10.1126/science.1223616 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Huang J, Ellinghaus D, Franke A, et al. . 1000 Genomes-based imputation identifies novel and refined associations for the Wellcome Trust Case Control Consortium phase 1 Data. Eur J Hum Genet 2012;20:801–5. 10.1038/ejhg.2012.3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.International HapMap Consortium. The International HapMap Project. Nature 2003;426:789–96. 10.1038/nature02168 [DOI] [PubMed] [Google Scholar]
  • 52.Schwenk J, Harmel N, Zolles G, et al. . Functional proteomics identify cornichon proteins as auxiliary subunits of AMPA receptors. Science 2009;323:1313–19. 10.1126/science.1167852 [DOI] [PubMed] [Google Scholar]
  • 53.Herring BE, Shi Y, Suh YH, et al. . Cornichon proteins determine the subunit composition of synaptic AMPA receptors. Neuron 2013;77:1083–96. 10.1016/j.neuron.2013.01.017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Wheeler E, Huang N, Bochukova EG, et al. . Genome-wide SNP and CNV analysis identifies common and low-frequency variants associated with severe early-onset obesity. Nat Genet 2013;45:513–17. 10.1038/ng.2607 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Teramoto H, Coso OA, Miyata H, et al. . Signaling from the small GTP-binding proteins Rac1 and Cdc42 to the c-Jun N-terminal kinase/stress-activated protein kinase pathway. A role for mixed lineage kinase 3/protein-tyrosine kinase 1, a novel member of the mixed lineage kinase family. J Biol Chem 1996;271:27225–8. 10.1074/jbc.271.44.27225 [DOI] [PubMed] [Google Scholar]
  • 56.Liu R, O'Connell M, Johnson K, et al. . Extracellular signal-regulated kinase 1/extracellular signal-regulated kinase 2 mitogen-activated protein kinase signaling and activation of activator protein 1 and nuclear factor kappaB transcription factors play central roles in interleukin-8 expression stimulated by monosodium urate monohydrate and calcium pyrophosphate crystals in monocytic cells. Arthritis Rheum 2000;43:1145–55. [DOI] [PubMed] [Google Scholar]
  • 57.Zeller T, Wild P, Szymczak S, et al. . Genetics and beyond—The transcriptome of human monocytes and disease susceptibility. PLoS ONE 2010;5:e10693 10.1371/journal.pone.0010693 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Mody GM, Tikly M, Kalla AA, et al. . Approach to arthritis: clinical guideline 2003. S Afr Med J 2003;93:949–60. [PubMed] [Google Scholar]
  • 59.AstraZeneca. AstraZeneca announces topline results from phase III monotherapy study of lesinurad in gout patients. [Press release] 13 December 2013. http://www.astrazeneca.com/Media/Press-releases/Article/13122013--astrazeneca-announces-topline-results-from-phase-iii (accessed 1 Jul 2014).
  • 60.Fleischmann R, Kerr B, Yeh LT, et al. . Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia. Rheumatology (Oxford) 2014;53:2167–74. 10.1093/rheumatology/ket487 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Web supplement
annrheumdis-2014-206191-s1.pdf (1.4MB, pdf)

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES